Twist Bioscience Co. (NASDAQ:TWST) COO Sells $97,426.49 in Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) COO Patrick John Finn sold 2,261 shares of the company's stock in a transaction that occurred on Wednesday, October 23rd. The shares were sold at an average price of $43.09, for a total transaction of $97,426.49. Following the sale, the chief operating officer now directly owns 159,483 shares of the company's stock, valued at approximately $6,872,122.47. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total transaction of $296,636.65.
• On Monday, August 5th, Patrick John Finn sold 2,885 shares of Twist Bioscience stock. The stock was sold at an average price of $39.93, for a total transaction of $115,198.05.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock traded up $0.36 during trading on Friday, hitting $40.60. The stock had a trading volume of 593,422 shares, compared to its average volume of 955,359. The firm's fifty day simple moving average is $43.89 and its 200-day simple moving average is $44.58. The stock has a market cap of $2.36 billion, a PE ratio of -12.08 and a beta of 1.77. Twist Bioscience Co. has a 12 month low of $14.42 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The firm had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. Twist Bioscience's revenue was up 27.7% compared to the same quarter last year. During the same quarter last year, the business posted ($1.01) EPS. Analysts expect that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of research reports. Evercore ISI upped their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Robert W. Baird increased their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a research report on Monday, August 5th. The Goldman Sachs Group increased their price objective on shares of Twist Bioscience from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, July 9th. Leerink Partners increased their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research report on Thursday, October 17th. Finally, Barclays lowered their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $51.22.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. SteelPeak Wealth LLC purchased a new position in Twist Bioscience in the 3rd quarter worth about $416,000. China Universal Asset Management Co. Ltd. increased its stake in Twist Bioscience by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,268 shares of the company's stock worth $509,000 after buying an additional 4,427 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after buying an additional 381 shares during the period. International Assets Investment Management LLC increased its stake in Twist Bioscience by 4,418.3% in the 3rd quarter. International Assets Investment Management LLC now owns 4,925 shares of the company's stock worth $223,000 after buying an additional 4,816 shares during the period. Finally, Signaturefd LLC increased its stake in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after buying an additional 306 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.